Physician profile
Mary Sedarous
NPI 1114187465
$14,829.58
in general payments reported to CMS, 2019-2025
77 companies · $2,163 in 2025
The $2,163 reported for 2025 was more than what 93% of Neuromusculoskeletal Medicine & Omm providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,597 · 2020: $1,566 · 2021: $2,297 · 2022: $2,484 · 2023: $2,618 · 2024: $2,105 · 2025: $2,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,885.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,582.79 | 2019-2025 | |
| Ucb, INC. | $1,352.42 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Abbvie INC. | $1,335.64 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Teva Pharmaceuticals USA, INC. | $1,208.80 | 2019-2025 | Austedo Xr, Ajovy, Austedo |
| Alexion Pharmaceuticals, INC. | $975.14 | 2019-2025 | Ultomiris |
| Biogen, INC. | $956.00 | 2019-2025 | Qalsody, Spinraza, Skyclarys |
| Pfizer INC. | $800.36 | 2019-2025 | |
| Lilly USA, LLC | $475.17 | 2019-2024 | Emgality, Reyvow, Amyvid |
| Argenx US, INC. | $398.68 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Sk Life Science, INC. | $306.39 | 2020-2025 | |
| Lundbeck LLC | $291.52 | 2021-2025 | Vyepti |
| Catalyst Pharmaceuticals, INC. | $274.42 | 2020-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $255.47 | 2022 | |
| Csl Behring | $230.28 | 2019-2024 | Hizentra |
| Kyowa Kirin, INC. | $221.59 | 2019-2024 | Nourianz |
Show all 77 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Sedarous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.